[1] 李灿晓,梁楠,李世杰,等. 淋巴细胞相关炎症指数预测甲状腺癌预后研究进展[J].中国实用外科杂志,2021,41(6):706-709.
[2] 白熠洲,郭佳宜,刘安阳,等. 中低危分化型甲状腺癌术后碘(131I)治疗对短期临床转归的影响[J].中国医刊,2019,54(11):47-51.
[3] CONSTANTINIDOU A ,ALIFERIS C ,TRAFALIS D T . Targeting programmed cell death-1 (PD-1) and ligand (PD-L1):a new era in cancer active immunotherapy[J].Pharmacol Ther,2019,194(1):84-106.
[4] 黄世杰. 抗体药物偶联物enfortumab vedotin伍用派姆单抗一线治疗晚期膀胱癌的Ⅰ期临床试验结果公布[J].国际药学研究杂志,2019,46(11):878.
[5] 武献珍,姚璧. 程序性死亡受体抑制剂派姆单抗治疗肺腺癌一例并文献复习[J].中国药物与临床,2018,18(1):115-117.
[6] 周梁. 分化型甲状腺癌的诊断与治疗[J].中华耳鼻咽喉头颈外科杂志,2007,42(12):962-964.
[7] JUWEID M E ,RABADI N J ,TULCHINSKY M ,et al. Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer:case study of Jordan[J].Endocrine,2021,73(3):633-640.
[8] CHOWDHURY S ,VEYHL J ,JESSA F ,et al. Programmned death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants[J].Oncotarget,2016,7(22):32318-32328.
[9] 吴宇平,张潇宇,陆克义. PD-L1在甲状腺癌中的作用机制及其在诊疗中的应用[J].国际肿瘤学杂志,2021,48(9):560-563.
[10] SPRANGER S,GAJEWSKI T F . Impact of oncogenic pathways on evasion of antitumour immune responses[J].Nat Rev Cancer,2018,18(3):139-147.
[11] GUNDA V ,GIGLIOTI B ,NDISHABANDI D ,et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer [J].Br J Cancer,2018,119(10):1223-1232.
[12] MEHNERT J M ,VARGA A ,BROSE M S ,et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced,PD-L1-positive papillary or fllicular thyroid cancer[J].BMC Cancer,2019,19(1):196.
[13] 曾飞,卢洁,孙仁浩,等. 程序性死亡受体-1及其配体抑制剂在头颈部鳞状细胞癌免疫治疗的研究进展[J].口腔疾病防治,2021,29(10):706-710.
[14] 李涛,陶然,张帆,等. 化疗联合免疫检查点抑制剂对局部晚期或转移性胃和胃-食管结合部癌患者的疗效及安全性分析[J].解放军医学院学报,2020,41(4):315-319.
2023, Vol. 40 
